Assessment of A new Strategy to Prevent Prescribing Errors Involving COVID-19 Patients in Community Pharmacies

dc.contributor.authorAbdel-Qader, Derar H.
dc.contributor.authorAl Meslamani, Ahmad Z.
dc.contributor.authorAlbassam, Abdullah
dc.contributor.authorAl Mazrouei, Nadia
dc.contributor.authorEl-Shara, Asma A.
dc.contributor.authorEl Sharu, Husam
dc.contributor.authorEbaed, Samah Bahy Mohammed
dc.contributor.authorIbrahim, Osama Mohamed
dc.contributor.departmentCenter for Health Innovation and Implementation Science
dc.date.accessioned2024-05-07T06:22:15Z
dc.date.available2024-05-07T06:22:15Z
dc.date.issued2022
dc.description.abstractBackground: Because COVID-19 patients are vulnerable to prescribing errors (PEs) and adverse drug events, designing and implementing a new approach to prevent prescribing errors (PEs) involving COVID-19 patients has become a priority in pharmacotherapy research. Objectives: To investigate whether using WhatsApp to deliver prescribing error (PE)-related clinical scenarios to community pharmacists could enhance their ability to detect PEs and conduct successful pharmaceutical interventions (PIs). Methods: In this study, 110 community pharmacies were recruited from different regions across Jordan and equally allocated to 2 groups. Over the course of 4 weeks, WhatsApp was used to send PEs-related clinical case scenarios to the active group. The second group was controlled with no clinical scenarios. After completion of the 4-week phase, pharmacists from both groups were asked to document PEs in COVID-19 patients and their interventions using a data-collection form. Results: The incidence of PEs in COVID-19 patients documented in the active group (18.54%) was higher than that reported in the control group (3.09%) (P = .001). Of the 6598 and 968 PIs conducted by participants working in the active and control group pharmacies, 6013 (91.13%) and 651 (67.25%) were accepted, respectively. The proportions of wrong drug (contraindication), wrong drug (unnecessary drug prescribed/no proof of its benefits), and omission of a drug between the active and control groups were 15.30% versus 7.21% (P = .001), 11.85% versus 6.29% (P = .03), and 17.78% versus 10.50% (0.01), respectively. Additionally, the proportions of lethal, serious, and significant errors were 0.74% versus 0.35% (P = .04), 10.52% versus 2.57% (0.002), and 47.88% versus 9.57% (0.001), respectively. Addition of drug therapy interventions (AOR = 0.62; 95% CI, 0.21-0.84) and errors with significant clinical seriousness (AOR = 0.32; 95% CI, 0.16-0.64). Conclusions PEs involving COVID-19 patients in community settings are common and clinically significant. The intervention assessed in this study could be promising for designing a feasible and time-efficient interventional tool to encourage pharmacists' involvement in identifying and correcting PEs in light of COVID-19.
dc.eprint.versionFinal published version
dc.identifier.citationAbdel-Qader DH, Al Meslamani AZ, Albassam A, et al. Assessment of A new Strategy to Prevent Prescribing Errors Involving COVID-19 Patients in Community Pharmacies. Hosp Pharm. 2022;57(5):654-665. doi:10.1177/00185787211073506
dc.identifier.urihttps://hdl.handle.net/1805/40503
dc.language.isoen_US
dc.publisherSage
dc.relation.isversionof10.1177/00185787211073506
dc.relation.journalHospital Pharmacy
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectCOVID-19 patients
dc.subjectPrescribing errors
dc.subjectClinical scenarios
dc.titleAssessment of A new Strategy to Prevent Prescribing Errors Involving COVID-19 Patients in Community Pharmacies
dc.typeArticle
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445540/
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Abdel-Qader2022HospitalPharmacy-PP.pdf
Size:
587.88 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: